The HCPLive Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.
October 3rd 2024
A study reveals that individuals with schizophrenia spectrum disorders experience high rates of comorbid mental health conditions and receive minimally adequate treatment.
September 26th 2024
September 20th 2024
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Antipsychotic Injections for Schizophrenia Linked to Decline in Hospital Readmissions
January 31st 2024In a study comparing readmission rates for patients with schizophrenia or schizoaffective disorder on oral or long-acting injections, investigators found after 30 days the readmission rate was 8.3% among patients who received pills and 1.9% among patients who received injections.
CBT May Normalize Fronto-Parietal Activation in Unmedicated Pediatric Anxiety
January 30th 2024After undergoing cognitive behavioral therapy, unmedicated pediatric patients with anxiety disorder experienced changes in activation in the fronto-parietal network regions including left and right supplementary motor area, middle frontal gyrus, and superior parietal lobule.
Single Substance Not Linked to Single Psychiatric Symptom in Adolescents
January 29th 2024A new survey study of high schoolers found alcohol, cannabis, and nicotine were linked to significant, moderate dose-dependent associations with worse symptoms of depression, anxiety, ADHD, general mental health, as well as suicidal thoughts.
Behavioral Activation Therapy Treats Depression in Patients with Heart Failure
January 26th 2024A new study found behavioral activation therapy is just as effective as antidepressants for treating depressive symptoms in patients with heart failure, with both treatments having a 50% reduction at months 3, 6, and 12.
Jacob Ballon, MD, MPH: Discusses Takeaways from Studying Long-Term Olanzapine and Samidorphan
January 17th 2024In an interview, Jacob Ballon, MD, MPH, discusses the significance of his team’s study which found olanzapine and samidorphan was well-tolerable for up to 4 years of treatment for schizophrenia and bipolar disorder treatment.
Increase in Depressive Symptoms Linked to Further Weight Gain in Overweight, Obesity
January 11th 2024For every increment increase in a participant’s usual score for depressive symptoms, investigators of a new study found weight increased a month later by 45g, only for participants with overweight and obesity.
Mindfulness-Oriented Recovery, Methadone Treatment Linked to Less Drug Use
January 3rd 2024Mindfulness-Oriented Recovery Enhancement plus methadone treatment is a promising treatment option for patients with opioid use disorder, having been significantly associated with less return to drug use and methadone treatment dropout, a new study found.
Parents Pass Down Psychiatric Conditions Due to a General Psychopathology Factor
December 22nd 2023In a new study, children had 8 - 40% higher odds of a psychiatric condition if their parents scored 1 SD above the mean on the general psychopathology. This demonstrates how parents with psychiatric disorders have a higher likelihood of passing it down to their children.
Tighter Versus Less-Tight Glycemic Treatment Compares Similarly for Gestational Diabetes Mellitus
December 19th 2023Tight glycemic target treatment compares similarly to less-tight glycemic target treatment in terms of how it affects the mental health status of women with gestational diabetes mellitus.
Daniel Karlin, MD: Topline MM-120 Data for Generalized Anxiety Disorder
December 15th 2023A phase 2b clinical trial met its primary endpoint with positive topline results, showing MM-120 (lysergide d-tartrate) can reduce symptoms of generalized anxiety disorder, reflected in the Hamilton Anxiety rating scale scores.